The substances utilized for what is commonly referred to as 'protein therapeutics' have one thing in common --- they are all composed primarily of á-amino acids; and these á-amino acids are linked together by a distinct chemical bond known as a “peptide” bond. Used in a variety of areas of medicine, they are among the most interesting pharmaceutical markets.
Above-Average Growth Rates
What makes protein therapeutics interesting? The market for protein-based therapeutics is one that is significant in its size and growing at a rate that is well above what one would call “average” for the therapeutics/pharmaceuticals industry. This makes them a continual topic of interest for researchers examining the pharmaceutical markets. Protein Therapeutics: (Monoclonal Antibodies, Plasma Proteins, Vaccines and Other Treatments) takes a detailed look at this market
The substances detailed in this report include:
For each of these categories, market forecasts to 2012 are provided.
A Thriving Field with Abundant Competition
At the present time, there are at least 213 companies active in various aspects of protein-based therapeutics development. This is at, or greater than, the saturation level for the industry at this time. Presently, the industry is at equilibrium --- companies at the lower end leaving and entering at about the same rate and a small number of protein-based therapeutics companies being acquired by the more-established participants.
A Report That Answers Key Questions about the Market
Dr. Kenneth Krul, PhD has surveyed the marketplace and in this volume reviews the key findings and conclusions about the current state of protein therapeutics. The report features forecasts for the main groups of protein therapeutics. Among the questions answered in this report:
How large is the market; how fast is the market growing; and is such growth sustainable?
What does the pipeline of products that are expected to sustain this growth look like?
To what extent is the growth in this market dependent on production introduction versus price-point for these products?
Is the development pipeline filled with similar products or direct alternatives such that product competition will be strong enough to significantly affect price-point?
What is the industry structure like? What changes can be expected in the structure of the industry and how will these changes affect market size and growth?